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Insufficient treatment of severe depression
in neuromyelitis optica spectrum disorder
ABSTRACT
Objective: To investigate depression frequency, severity, current treatment, and interactions with
somatic symptoms among patients with neuromyelitis optica spectrum disorder (NMOSD).
Methods: In this dual-center observational study, we included 71 patients diagnosed with
NMOSD according to the International Panel for NMODiagnosis 2015 criteria. The Beck Depres-
sion Inventory (BDI) was classified into severe, moderate, or minimal/no depressive state cate-
gory. We used the Fatigue Severity Scale to evaluate fatigue. Scores from the Brief Pain
Inventory and the PainDETECTQuestionnaire were normalized to estimate neuropathic pain. Psy-
chotropic, pain, and immunosuppressant medications were tabulated by established classes.
Results: Twenty-eight percent of patients with NMOSD (n 5 20) had BDI scores indicative of
moderate or severe depression; 48% of patients (n 5 34) endorsed significant levels of neuro-
pathic pain. Severity of depression was moderately associated with neuropathic pain (r5 0.341,
p , 0.004) but this relationship was confounded by levels of fatigue. Furthermore, only 40% of
patients with moderate or severe depressive symptoms received antidepressant medical treat-
ment. Fifty percent of those treated reported persistent moderate to severe depressive symp-
toms under treatment.
Conclusions: Moderate and severe depression in patients with NMOSD is associated with neuro-
pathic pain and fatigue and is insufficiently treated. These results are consistent across 2
research centers and continents. Future research needs to address how depression can be effec-
tively managed and treated in NMOSD. Neurol Neuroimmunol Neuroinflamm 2016;3:e286; doi:
10.1212/NXI.0000000000000286
GLOSSARY
AQP4 5 aquaporin-4; BDI 5 Beck Depression Inventory; BPI 5 Brief Pain Inventory; EDSS 5 Expanded Disability Status
Scale; FSS5 Fatigue Severity Scale; JHU 5 Johns Hopkins Hospital; NMO 5 neuromyelitis optica; NMOSD 5 neuromyelitis
optica spectrum disorder; ON 5 optic neuritis; PDQ 5 PainDETECT Questionnaire; SNRI 5 serotonin norepinephrine reup-
take inhibitor; SSRI 5 selective serotonin reuptake inhibitor; TM 5 transverse myelitis.
Depression is one of the most common and debilitating comorbidities of neurologic diseases. It
has been associated with decreased quality of life, lower treatment adherence rate, increased dis-
ease severity, higher unemployment rates, and cognitive deficits among neurology patients.1
Depression is also exacerbated by symptoms of fatigue2 and pain,3 the interaction of which has
a direct effect on quality of life.
Neuromyelitis optica (NMO) spectrum disorder (NMOSD) is an autoimmune disease of the
CNS associated with serum antibodies to the astrocyte water channel aquaporin-4 (AQP4).4
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NMOSD is predominantly characterized by
optic neuritis and transverse myelitis leading
to blindness, weakness, numbness, and pain.5
Brain areas typically associated with organic
depression,6,7 such as prefrontal areas, limbic
systems, and the hippocampus, are usually
spared among patients with NMOSD.8–10
However, recent studies have reported a high
prevalence of depression within this popula-
tion and have claimed that patients with
NMOSD present with depression severity
comparable to that experienced by patients
with multiple sclerosis.11–13 Due to the low
prevalence of NMOSD,14,15 previous studies
have employed smaller samples and interna-
tional comparisons are currently missing.
Therefore, it is imperative to investigate the
elements of depression among patients with
NMOSD within a larger multicenter cohort.
We assessed the frequency and severity of
depressive states and their interaction with
somatic symptoms in a multicenter observa-
tional investigation across 2 continents. Our
secondary objective was to evaluate the associ-
ation of disease-modifying, pain, and psycho-
tropic therapy with current depressive and
somatic symptoms.
METHODS Sample. We collected data in a cross-sectional
observational study at 2 major academic research centers: the
Charité Universitätsmedizin, Berlin, Germany (the Charité)
and the Johns Hopkins Hospital (JHU), Baltimore, MD.
Inclusion criteria were formal diagnosis of NMOSD accord-
ing to the International Panel for NMO Diagnosis 2015 updated
diagnostic criteria16 and conversational level of the primary lan-
guage spoken at the recruiting center. Exclusion criteria were age
over 70 years and myelin oligodendrocyte glycoprotein antibody
seropositivity when available.17 All patients at each center who
satisfied the inclusion criteria and did not meet the exclusion
criteria were included in this study.
Standard protocol approvals, registrations, and patient
consents. Study initiation followed research protocol approval
by the internal ethics review board at each institution. Patients
provided written informed consent and underwent a formal neu-
rologic examination.
Assessment of depressive symptomatology. To evaluate
depressive symptoms, we administered the Beck Depression
Inventory (BDI)–IA18 at the Charité and BDI-II version19 at
JHU. Both versions contain 21 questions with a maximum
total score of 63. Total BDI-IA scores were adjusted to BDI-II
scores according to the BDI-II Manual.20 We interpreted BDI
scores as follows: 0–9 as nondepressive affect; 10–19 as minimal
mood disturbance; 20–29 as moderate depressive state; 30 and
above as severe depressive state.20 Consistent with prior literature,
we categorized patients whose total BDI score was $20 with
a high likelihood of clinical depression.21,22
Assessment of fatigue. We assessed fatigue with the Fatigue
Severity Scale (FSS).23 This questionnaire measures severity of
fatigue in 9 questions on a 7-point Likert scale. A threshold
level of 4 has been shown to differentiate individuals with and
without significant levels of fatigue.2,23,24
Neuropathic pain. The Brief Pain Inventory (BPI) and the
PainDETECT Questionnaire (PDQ) were used to evaluate pres-
ence and severity of pain at JHU and the Charité, respectively.
The BPI was created to measure pain level from 0 (least) to 10
(worst) in cancer patients in the United States.25 Among patients
with nonmalignant chronic pain, an average BPI score of 6.8 (SD
1.8) has been reported26 and recent work has shown that patients
with NMO average a BPI score of 5.9 (SD 2.9).27 Based on these
findings, we adopted a conservative cutoff score of 6: patients who
scored ,6 on the BPI index were classified as not having pain
with a significant neuropathic component while those scoring$6
were classified as experiencing neuropathic pain. Although a con-
servative cutoff score of BPI5 6 may have decreased sensitivity of
this measure, it minimized overestimating the prevalence of neu-
ropathic pain.
The PDQ was created to differentiate nociceptive from neu-
ropathic pain in low back pain patients.28 According to validation
data representative of the German population,26 a PDQ score of
12 or higher is indicative of pain with a primarily neuropathic
etiology. We classified individuals with scores $12 as experienc-
ing neuropathic pain, and those with scores ,12 as not experi-
encing pain with a substantial neuropathic component.
To allow for a quantitative comparison of pain within the
entire cohort, we tested the distribution of BPI and PDQ scores
for normality with Kolmogorov-Smirnov tests and standardized
individual values to the mean of their respective recruiting center
sample. After pooling, z scores of pain levels used in all statistical
tests ranged from 21.68 to 2.085 (mean 20.0001, SD 0.993),
representing average and SD of pain within our cohort.
Current pharmacotherapy. We recorded immunosuppressive
preventive therapy for NMOSD, including rituximab, azathio-
prine, mycophenolate, and methotrexate.29,30 Pain medications
included anticonvulsants (gabapentin, pregabalin, carbamaze-
pine, clonazepam, oxcarbazepine, topiramate, zonisamide),
muscle relaxants (baclofen, tizanidine, diazepam, dantrolene,
tolperisone), tricyclic antidepressants (amitriptyline), opioids
(tramadol, fentanyl, oxycodone), and a selective serotonin nor-
epinephrine reuptake inhibitor (SNRI; duloxetine). The nature
and etiology of pain reported by patients with NMOSD is often
managed with multiple medication categories, most frequently
with anticonvulsants and low-dose tricyclic antidepressants.31–33
Psychoactive medications included SNRI (duloxetine, venlafaxine,
milnacipran), selective serotonin reuptake inhibitors (SSRI;
citalopram, escitalopram, sertraline), tricyclic antidepressants
(amitriptyline), and atypical antidepressants (mirtazapine).
Statistical analyses. We examined the demographic and clin-
ical characteristics of patients with BDI $20 and those with
BDI ,20. Continuous variables between groups were com-
pared with independent samples t tests; categorical variables,
with Pearson x2 tests; effect sizes are reported with Cohen d.
Distributions of all outcome variables were assessed for normal-
ity with Kolmogorov-Smirnov tests. Nonparametric tests were
used to assess non-normally distributed continuous outcomes,
ordinal variables, and the effect of treatment on the primary
outcomes. We performed Pearson correlations of primary
outcomes and partial correlations adjusting for confounders.
We utilized a stepwise multiple regression to evaluate the
variability of BDI scores attributable to somatic symptoms
2 Neurology: Neuroimmunology & Neuroinflammation
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
and clinical and demographic factors. All tests were 2-tailed and
significance was indicated when p , 0.05.
RESULTS Demographics. Seventy-one patients with
NMOSD (n 5 36 at JHU, n 5 35 in Berlin),
89% of whom were AQP4-positive, were enrolled
in this study. Ninety-three percent of all participants
were female; the female to male ratio was typical of
relapsing NMOSD.9 The mean disease duration was
7.1 years (SD 5.6) and the median Expanded
Disability Status Scale (EDSS) of the sample was
4.5 (range 0–8). Participants did not differ on
demographic and clinical variables between
centers, except on ethnic distribution and EDSS.
Table 1 illustrates the characteristics of the entire
cohort and clinical and demographic characteristics
of the sample by recruitment center are shown in
table e-1 at Neurology.org/nn.
Frequency of moderate or severe depression. We found
that 30% (n 5 21) of patients with NMOSD scored
between 10 and 19, consistent with a dysphoric state;
22% (n 5 16) scored between 20 and 29, consistent
with moderate depressive state; and 6% (n 5 4)
scored above 30, consistent with severe depression.
Fifteen patients with NMOSD (21%) also endorsed
suicidal ideation or behavior, indicated by a score of 1
or greater on item 9 of the BDI. Seventy-five percent
of patients who reported suicidal ideation or behavior
scored 20 or greater and the distribution of suicidal
patients did not differ across centers.
Patients with BDI scores $20 and patients with
BDI scores ,20 did not differ with regard to age
(mean 47.1, SD 11.1 vs mean 45.7, SD 12.2, p .
0.1), disease duration (mean 5.7, SD 4.2 vs mean
7.7, SD 5.3, p. 0.1), or EDSS (median 5.5, 1–7 vs
median 4.0, 0–8,U5 421.5, p. 0.1). Distribution
of BDI scores was similar across the 2 recruiting
centers. The figure illustrates the severity of depres-
sive symptoms by center (A) and antidepressant
treatment (B).
History and relapse rate of optic neuritis (ON),
transverse myelitis (TM), or both ON and TM was
available only for the cohort from the Charité. BDI
scores between patients with any of the 3 classifica-
tions (ON, TM, or ON and TM) did not differ, F5
0.667, p 5 0.520. Furthermore, relapse rate was not
associated with BDI scores, Pearson r(26) 5 0.212,
p 5 0.297. The 6 patients with monophasic disease
had an average BDI score mean 5 14.5 (SD 9.1),
which was not different from the entire cohort mean.
Depression associated with higher levels of fatigue and
neuropathic pain. Patients with moderate to severe
depressive states had significantly higher FSS scores
than patients with mild or minimal depressive states
and experienced neuropathic pain of greater inten-
sity. With the exception of one patient, all who
scored 20 or greater on the BDI had elevated FSS
scores (table 2). BDI scores were moderately corre-
lated with standardized pain scores, Pearson r(71)5
0.341, p , 0.004. However, when fatigue was con-
trolled for, this association became weaker, Pearson
r(66) 5 0.140, p 5 0.254.
In a multiple regression model, pain and fatigue
accounted for 23% of the variance in depressive
states, R2 5 0.23, F2,66 5 9.67, p , 0.001. Demo-
graphic or clinical parameters, including EDSS, did
not contribute to explaining the variance of depressive
states beyond pain and fatigue. Of note, lower disease
duration (b 5 20.247, p 5 0.244) and greater
EDSS (b 5 0.772, p 5 0.271) were associated with
an increase in BDI score.
Somatic symptoms and prescription medication therapy.
Of the 68 participants who provided information
on antidepressant medications, a total of 20 pa-
tients received antidepressant pharmacotherapy,
either as psychiatric or pain therapy. There was
no difference in the distribution of antidepressant
medications reported by patients across centers,
Pearson x2(3,68) 5 5.896, p 5 0.117. Table e-2
Table 1 Participant characteristics
Entire cohort (n 5 71)
Demographic characteristics
Age, y 46.1 (11.8)
Sex, %
Female 93
Male 7
Ethnicity, %
European descent 75
African descent 22
Asian descent 3
Clinical characteristics
AQP4 seropositive1, % 89
EDSS 4.5 (0–8)
Disease duration 7.1 (5.6)
BDI score 13.6 (9.2)
FSS score 4.4 (1.7)
Pain Z score 0.0 (1.0)
PDQ 12.8 (8.7)
BPI 4.7 (2.7)
Abbreviations: AQP4 5 aquaporin-4; BDI 5 Beck Depres-
sion Inventory adjusted total scores; BPI5 Brief Pain Inven-
tory; EDSS 5 Expanded Disability Status Scale; FSS 5
Fatigue Severity Scale; PDQ 5 PainDETECT Questionnaire.
Pain Z score 5 normalized BPI and PDQ scores. Age, dis-
ease duration, BDI, FSS, and pain Z scores are reported as
mean (SD). EDSS is reported as median (range).
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presents the distribution of medications by center.
Fifty percent of those (10 out of 20) still scored 19
or above on the BDI and only 4 scored within the
normal range of BDI. Medically treated patients
were 40% (8 out of 20) of the total number of
patients with BDI score $20. Half of the patients
categorized as severely depressed (2 out of 4), based
on a BDI score above 30, received antidepressant
medication therapy. A total of 6 out of 16 patients
with moderate depression received antidepressant
therapy. Among patients who reported moderate
depression, antidepression medications included tricy-
clics (n 5 3), atypical antidepressants (n 5 2), and
SNRI (n 5 1); 3 of these patients were receiving
antidepressants for the indication of pain and not
depression.
Fifty-two percent of patients received pain medi-
cation therapy (36 out of 69), the majority (56%,
20 out of 36) filling current prescriptions for more
than one category of pain medication. Of note, the
distribution of pain medications differed across re-
cruiting centers, Pearson x2(3,69) 5 11.887, p 5
0.018 (table e-2). Twenty-five percent (9 out of 36)
were taking only anticonvulsants, 17% (6 out of 36)
were taking only muscle relaxants, and 1 patient was
prescribed the opioid/SNRI tramadol. All patients
who received low-dose antidepressants as indicated
for pain treatment were also receiving other classes
of pain medications. Among patients with NMOSD
prescribed any pain medications, 58% (21 out of 36)
still endorsed current pain above the threshold for
clinically significant neuropathic pain (PDQ .12
and BPI .6).
Patients who receive pain medications and no
psychopharmacotherapy have lower depressive states
and fatigue. Patients who received only pain therapy
scored almost 8 points lower on the total BDI score
(mean 10.26, SD 5.32, n 5 19) than those who
received both psychotropic and pain medications
(mean 18.00, SD 10.78, n 5 16, t[33] 5 2.614,
p 5 0.016, d 5 0.911). Patients who took low-
dose antidepressants indicated for pain treatment
Figure Depression severity
(A) Labeled by recruiting center. (B) Labeled by antidepressant medication therapy. BDI5Beck Depression Inventory; JHU5 Johns Hopkins Hospital; SNRI5
serotonin norepinephrine reuptake inhibitor; SSRI 5 selective serotonin reuptake inhibitor.
Table 2 Prevalence of fatigue and pain in depressed and nondepressed
patients with neuromyelitis optica spectrum disorder
Syndrome
Not depressed,
BDI <20
Depressed,
BDI ‡20 Test statistic Effect size
Fatigue
FSS score 4.05 (1.72) 5.24 (1.47) t(67) 5 2.72 d 5 0.74
Prevalence 0.57 0.90 x2(2) 5 6.90 V 5 0.31
Neuropathic pain
Z score 20.20 (0.98) 0.50 (0.85) t(69) 5 2.78 d 5 0.76
Prevalence 0.41 0.65 x2(2) 5 3.27 V 5 0.22
Abbreviations: BDI 5 Beck Depression Inventory adjusted total scores; FSS 5 Fatigue
Severity Scale.
Pain Z score 5 Brief Pain Inventory and PainDETECT Questionnaire scores normalized to
the sample mean. Values are mean (SD) or proportions.
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were included in the pain and antidepressants
medications group. The category of
psychopharmacologic therapy did not have an effect
on BDI scores stratified by pain medication. Further,
among the 16 patients who received both
psychotropic and pain medications, half had a BDI
score .20, in comparison to only 2 among the 19
patients who received only pain medications.
Patients with NMOSD who received only pain
therapy had lower fatigue scores (mean 4.47, SD
1.78, n 5 19) than patients who received both pain
and psychoactive medications (mean 4.60, SD 1.70,
n5 16) and patients who received only psychotropic
medications (mean 4.95, SD 1.19, n 5 4). In com-
parison, patients with NMOSD who received neither
pain nor psychoactive medications had an average
FSS score mean 4.00, SD 1.70, n 5 27. This differ-
ence in fatigue scores did not reach significance.
Immunosuppressive therapy is differentially associated
with depression, fatigue, and pain. When stratified by
current immunosuppressant therapy, patients who
were treated with rituximab scored lowest on the
BDI (mean 11.83, SD 7.51, n 5 41) compared to
patients who received mycophenolate (mean 16.27,
SD 11.70, n 5 11) and patients receiving azathio-
prine (mean 17.13, SD 11.18, n 5 14). A nonpara-
metric test of rank differences did not reach
significance. Additionally, across patients who
received rituximab, BDI scores were similar regardless
of pain or psychotropic medications. Table 3 illus-
trates pain, fatigue, and depression levels tabulated by
immunosuppressant medication.
DISCUSSION In this transnational comparison of
depressive symptomatology in NMOSD, moderate
to severe depression was observed in 28% of patients.
Our results exhibit a consistency of depressive and
somatic symptomatology across 2 research centers
and continents. We observed no significant differen-
ces in the prevalence or severity of depression, fatigue,
or pain between patients in Germany and patients in
the United States. These findings are in line with
recent research from the United Kingdom, France,
and Japan.20,22,34
As established in cohorts with major depression,
suicidality was the most common symptom associ-
ated with high scores on the BDI.35,36 Prevalence
and severity of BDI scores were not associated with
history of myelitis or optic neuritis. Further, within
our sample, patients with moderate to severe depres-
sion had significantly higher levels of pain and fatigue
than patients with NMOSD with no or minimal
depressive symptoms. Similar findings are also re-
flected in previous studies largely demonstrating a pos-
itive correlation between pain and depressive
affect3,37,38 as well as between fatigue and depressive
affect.39,40,e1
Although pain is moderately and significantly cor-
related with depression among patients with
NMOSD, levels of fatigue account for the majority
of this association. Interestingly, physical disability
or disease duration did not contribute significantly
to the variance of depressive states. This provides fur-
ther evidence for pain as antecedent to depression
proposed by Fishbain et al.3 Our study design pre-
vents us from showing a causal relationship; however,
when stratified by immunosuppressant therapy, we
observed that BDI scores are high when levels of pain
and fatigue are inversely related. This may indicate
that the interaction of fatigue and pain is differentially
modulated by immunosuppressant therapy and spe-
cifically contributes to depressive mood in this
cohort.
We also show that despite receiving antidepressant
medications, half of patients with NMOSD still
scored 20 or above on the BDI, suggesting insuffi-
cient or inadequate management of depressive symp-
tomatology. Interestingly, we observed that if taken
concurrently with pain medications, antidepressant
medication therapy is associated with significantly
higher BDI scores. Although these results must be in-
terpreted with caution due to our small sample sizes,
they may suggest that patients who experience only
pain, and therefore take only pain medications, report
lower depression levels. However, when depressive
states are comorbid with pain, the additional burden
appears not adequately alleviated despite multiple
classes of pharmacotherapy.
Prescriptions of pain medications vary greatly
among patients taking different disease-modifying
therapies. However, there were no statistically signif-
icant differences in depression severity among pa-
tients treated with different disease-modifying
therapies. The cross-sectional design of our study
does not allow us to infer whether immunosuppres-
sant, pain, and depression therapy specifically affect
Table 3 Beck Depression Inventory adjusted total scores (BDI), Fatigue
Severity Scale (FSS), and Brief Pain Inventory/PainDETECT
Questionnaire scores stratified by immunosuppressant medication
Immunosuppressant therapya
p Valueb
Rituximab
(n 5 41)
Azathioprine
(n 5 14)
Mycophenolate
(n 5 11)
BDI score 11.83 (7.51) 17.36 (11.18) 16.27 (11.70) 0.242
FSS score 4.54 (1.67) 4.25 (1.78) 3.89 (2.18) 0.672
Neuropathic pain Z score 0.02 (1.03) 20.45 (1.07) 0.42 (0.72) 0.086
Pain Z score 5 Brief Pain Inventory and PainDETECT Questionnaire scores normalized to
the sample mean.
Values are mean (SD).
a The one patient who was taking methotrexate was excluded from this analysis.
bSignificance results from Kruskal-Wallis nonparametric rank test.
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depressive symptoms, fatigue, or pain. Future
research should address the specifics of these interac-
tions with larger cohorts in longitudinal or random-
ized case-control studies.
Our study had some limitations. First, we utilized
different versions of the BDI in each research center.
BDI-IA probes for responses pertaining to the past
week and BDI-II probes for responses pertaining to
the past 2 weeks. We adjusted the total scores of
BDI-IA to those of BDI-II as recommended by Beck
et al.20 and used only the adjusted BDI scores in our
analyses. We selected a conservative cutoff score of 20
to classify individuals as depressed. In line with cur-
rent research and clinical recommendations, we
define depression as a syndrome of affective and psy-
chosomatic symptoms, and do not imply a diagnosis
of major depressive disorder.e2,e3
Another limitation was the use of different scales
to measure pain at each center. The PDQ and the
BPI are similar as both measure severity and fre-
quency of neuropathic pain. However, the former
captures pain within the past 4 weeks, while the lat-
ter captures pain within the last 24 hours. This was
an inherent weakness in the design of our study,
which we addressed by normalizing PDQ and BPI
scores to allow for comparison of pain levels within
our cohort. Further, we could not control for preex-
isting depression or other therapies, such as psycho-
therapy, and did not have information on duration
of treatment with antidepressants. All of these
important factors would affect the interpretation of
our results.
In the current study, we report that 28% of pa-
tients with NMOSD present with moderate to
severe depressive symptomatology, which is substan-
tially above the global estimated rate of 5.5%–5.9%
of depression in the general populatione3 and is com-
parable to the 23.7% (confidence interval 17.4%–
30%) prevalence rate of depression observed among
patients with multiple sclerosis.e4 Moreover, we
observed that the majority of patients who report
depressive symptoms indicative of moderate to
severe depressive states do not receive appropriate
antidepressant pharmacotherapy, suggesting insuffi-
cient or inadequate management of depressive
symptomatology among patients with NMOSD.
We also show that disease-modifying and pain ther-
apy may modulate levels of depressive symptomatol-
ogy, and suggest that fatigue and pain may confound
this interaction. Future prospective and longitudinal
studies with larger cohorts are needed to support our
results.
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